Avantor, Inc. (NYSE:AVTR) Shares Purchased by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lifted its position in Avantor, Inc. (NYSE:AVTR) by 45.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 86,225 shares of the company’s stock after purchasing an additional 26,884 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Avantor were worth $2,231,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in AVTR. 1832 Asset Management L.P. lifted its position in Avantor by 1,634.9% during the 2nd quarter. 1832 Asset Management L.P. now owns 8,530,118 shares of the company’s stock worth $180,839,000 after acquiring an additional 8,038,451 shares during the period. CCLA Investment Management lifted its position in Avantor by 147,220.3% during the 1st quarter. CCLA Investment Management now owns 4,720,144 shares of the company’s stock worth $120,828,000 after acquiring an additional 4,716,940 shares during the period. Sound Shore Management Inc. CT acquired a new stake in Avantor during the 2nd quarter worth approximately $76,412,000. Canada Pension Plan Investment Board lifted its position in Avantor by 6.8% during the 2nd quarter. Canada Pension Plan Investment Board now owns 22,927,325 shares of the company’s stock worth $486,059,000 after acquiring an additional 1,463,695 shares during the period. Finally, Magnetar Financial LLC acquired a new stake in Avantor during the 1st quarter worth approximately $35,154,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Avantor news, CAO Steven W. Eck sold 3,525 shares of the firm’s stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the completion of the transaction, the chief accounting officer now owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 1.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have weighed in on AVTR. TD Cowen increased their price objective on Avantor from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, July 29th. UBS Group cut their target price on Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Tuesday, October 8th. Stifel Nicolaus increased their target price on Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a research note on Monday, July 29th. Royal Bank of Canada reissued an “outperform” rating and set a $34.00 target price on shares of Avantor in a research note on Thursday, September 26th. Finally, Barclays cut their target price on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $27.57.

Avantor Stock Performance

NYSE AVTR opened at $22.59 on Friday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. The business has a 50 day moving average price of $24.91 and a 200 day moving average price of $24.12. The company has a market capitalization of $15.37 billion, a P/E ratio of 49.11, a PEG ratio of 2.78 and a beta of 1.35. Avantor, Inc. has a 1-year low of $18.08 and a 1-year high of $28.00.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.